Schizophrenia : News
Print
Email
SaveHealthline's Premium Tools
Healthline Part D Plan Selector
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
|
The Committee for Medicinal Products for Human Use has recommended European approval of Olanzapine Long-acting Injection , known in Europe by the trade name Zypadhera , for maintenance treatment of adult ...
|
|
The Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Zypadhera for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during ...
|
|
In a recent Value in Health article, researchers from the University of Southern California School of Pharmacy have documented the sensitivity of head-to-head drug comparisons based on existing data to sample ...
|
|
Although many people do not worry about developing the psychiatric disorder schizophrenia, as less than 1 percent of people feel the effects of the disease over their lifetime, some have to deal with the ...
|
|
Sep 23, 2008 - In a new paper published in the online open-access journal PLoS ONE, http://dx.plos.org/10.1371/journal.pone.0003150, David Pickar and colleagues of Gabriel Sciences report that 74.5% of 200 ...
|
|
The second-generation antipsychotics risperidone and olanzapine are no more effective than the first-generation drug molindone in treating early-onset schizophrenia and schizoaffective disorder, according to a ...
|
|
AUSTIN Texas has spent nearly $300 million since 2003 on expensive anti-psychotic medications for poor children drugs that cost more, have worse side effects in kids and are no more effective than older ...
|
|
THE newer drugs for treating schizophrenia have come under such a cloud in recent years that it's no surprise to learn of another setback: they work no better than an older, less expensive drug in children and ...
|
|
Memory Pharmaceuticals Corp. today announced that it has amended its nicotinic alpha-7 receptor agonist agreement with Roche to expand the Phase 2 development program for R3487/MEM 3454 in cognitive impairment ...
|
|
Mylan Inc. received approval from the Food and Drug Administration to manufacture and market Risperidone tablets, used to treat schizophrenia and bipolar disorder.
|
|
Mylan Inc today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Risperidone Tablets ...
|
|
Ingram Micro Inc. said Tuesday that it has cut its expected revenue for the third quarter to range from $8.3 billion to $8.6 billion.
|
|
The two most frequently prescribed antipsychotic drugs for children and adolescents offer no additional benefit and are more likely to cause side effects than an older, less costly medication, according to a ...
|
|
A comparison of medications for severe mental illness shows that an old drug works just as well as new ones for teenagers, plus it doesn't cause the weight gain that has worried patients, parents and doctors, ...
|
|
When scientists learned that PCP can cause every single symptom of schizophrenia, they wondered if chemicals that have the opposite effect could fight mental disorders.
|
 |
 |
Home | About | Health Experts | Careers | Site Map | Feedback | Help | Health Tools | Tell a Friend
Advertise | Terms of Use | Privacy Policy
Advertise | Terms of Use | Privacy Policy
Copyright © 2005 - 2008 Healthline Networks, Inc. All rights reserved.